Surgery: light – thermal – and electrical application – Light – thermal – and electrical application
Reissue Patent
2005-01-28
2011-11-22
Getzow, Scott M (Department: 3762)
Surgery: light, thermal, and electrical application
Light, thermal, and electrical application
C514S821000
Reissue Patent
active
RE042961
ABSTRACT:
Atrial arrhythmias, a major contributor to cardiovascular morbidity, are believed to be influenced by autonomic nervous system tone. The main purpose of this invention was to highlight new findings that have emerged in the study of effects of autonomic nervous system tone on atrial arrhythmias, and its interaction with class III antiarrhythmic drug effects. This invention evaluates the significance of sympathetic and parasympathetic activation by determining the effects of autonomic nervous system using a vagal and stellar ganglions stimulation, and by using autonomic nervous system neurotransmitters infusion (norepinephrine, acetylcholine). This invention evaluates the autonomic nervous system effects on the atrial effective refractory period duration and dispersion, atrial conduction velocity, atrial wavelength duration, excitable gap duration during a stable circuit (such atrial flutter circuit around an anatomical obstacle), and on the susceptibility of occurrence (initiation, maintenance and termination) of atrial re-entrant arrhythmias in canine. This invention also evaluates whether autonomic nervous system activation effects via a local neurotransimitters infusion into the right atria can alter those of class III antiarrhythmic drug, sotalol, during a sustained right atrial flutter. This invention represents an emergent need to set-up and develop a new class of anti-cholinergic drug therapy for the treatment of atrial arrhythmias and to combine this new anti-cholinergic class to antiarrhythmic drugs. Furthermore, this invention also highlights the importance of a local application of parasympathetic neurotransmitters/blockers and a catheter ablation of the area of right atrium with the highest density of parasympathetic fibers innervation. This may significantly reduce the occurrence of atrial arrhythmias and may preserve the antiarrhythmic effects of any drugs used for the treatment of atrial re-entrant arrhythmias.
REFERENCES:
patent: 4707499 (1987-11-01), Baran et al.
patent: 4886822 (1989-12-01), Shibuya et al.
patent: 5330507 (1994-07-01), Schwartz
patent: 5575766 (1996-11-01), Swartz
patent: 5617854 (1997-04-01), Munsif
patent: 5690681 (1997-11-01), Geddes et al.
patent: 5700282 (1997-12-01), Zabara
patent: 5919188 (1999-07-01), Shearon et al.
patent: 5954665 (1999-09-01), Ben-Haim
patent: 6161543 (2000-12-01), Cox
patent: 6292695 (2001-09-01), Webster et al.
patent: 6296630 (2001-10-01), Altman et al.
patent: 6502576 (2003-01-01), Lesh
patent: 2001/0044619 (2001-11-01), Altman
patent: 2009/0253974 (2009-10-01), Rahme
Allessie MA, Lammers WJ, Bonke IM, and Hollen J., “Intra-atrial reentry as a mechanism for atrial flutter induced by acetylcholine and rapid pacing in the dog,” Circulation. Jul. 1984;70(1):123-35.
Boyden P., “Models of atrial reentry,” Journal of Cardiovascular Elecrophysiology, 1995;6:313-24.
Carlson MD, Geha AS, Hsu J, Martin PJ, Levy MN, Jacobs G, Waldo AL., “Selective stimulation of parasympathetic nerve fibers to the human sinoatrial node,” Circulation. Apr. 1992;85(4):1311-7.
Chandler MP, DiCarlo SE., “Sinoaortic denervation prevents postexercise reductions in arterial pressure and cardiac sympathetic tonus,”, Am J. Physiol. Dec. 1997;273(6 Pt 2):H2738-45.
Chiou CW, Eble JN, and Zipes DP, “Efferent vagal innervation of the canine atria and sinus and atrioventricular nodes. The third fat pad.,” Circulation 1997;95:2573-2584.
Coumel P., “Cardiac arrhythmias and the autonomic nervous system,” J. Cardiovasc Electrophysiol. Jun. 1993;4(3):338-55.
Coumel P, Leenhardt A., “Mental activity, adrenergic modulation, and cardiac arrhythmias in patients with heart disease,” Circulation. Apr. 1991;83(4 Suppl)II58-70.
Derakhchan K, Page P, Lambert C, and Kus T., “Effects of procainamide and propafenone on the composition of the excitable gap in canine atrial reentry tachycardia,” Journal of Pharmacology and Experimental Therapeutic, 1994; 270:47-54.
Eckberg DL, “Parasympathetic cardiovascular control in human disease: a critical review of methods and results,” Am J. Physiol. Nov. 1980;239(5):H581-93.
Frame LH, Page RL, Hoffman BF., “Atrial reentry around an anatomic barrier with a partially refractory excitable gap. A canine model of atrial flutter,” Circ Res. Apr. 1986;58(4):495-511.
Furukawa Y, Wallick DW, Carlson MD, and Martin PJ., “Cardiac electrical responses to vagal stimulation of fibers to discrete cardiac regions,” Am J. Physiol. Apr. 1990;258(4 Pt 2):H1112-18.
Furukawa Y, Wallick DW, Carlson MD and Martin P., “Prolongation of cardiac cycle length attenuates negative dromotropic response to selective vagal stimuli,” J Auton Nerv Syst. Oct. 1989;28(1):43-50.
Furukawa Y, Hoyano Y, Chiba S., “Parasympathetic inhibition of sympathetic effects on sinus rate in anesthetized dogs,” Am J. Physiol. Jul. 1996;271(1 Pt 2):H44-50.
Hashimoto K, Chiba S, Tanaka S, Hirata M, Suzuki Y., “Adrenergic mechanism participating in induction of atrial fibrillation by ACh,” Am J Physiol. Nov. 1968;215(5):1183-91.
Hedman AE, Hartikainen JE, Tahvanainen KU, Hakumaki MO., “The high frequency component of heart variability reflects cardiac parasympathetic modulation rather than parasympathetic ‘tone’,” Acta Physiol Scand. Nov. 1995;155(3):267-73.
Hedman AE, Tahvanainen KU, Hartikainen JE, Hakumaki MO., “Effect of sympathetic modulation and sympatho-vagal interaction on heart rate variability in anaesthetized dogs,” Acta Physiol Scand. Oct. 1995;155(2):205-14.
Henning RJ, Khalil IR, and Levy MN., “Vagal stimulation attenuates sympathetic enhancement of left ventricular function,” American Journal of Physiology, 1990; 258:H1470-75.
Hoyano Y. Furukawa Y, Kasama M, Chiba S., “Parasympathetic inhibition of sympathetic effects on atrioventricular conduction in anesthetized dogs,” Am J Physiol. Oct. 1997;273(4 Pt 2):H1800-6.
Inoue H. Matsuo H, Takayanagi K, Murao S., “Clinical and experimental studies of the effects of atrial extrastimulation and rapid pacing on atrial flutter cycle. Evidence of macro-reentry with an excitable gap,” Am J. Cardiol. Oct. 1981;48(4):623-31.
Jalife J, Moe GK., “Phasic effects of vagal stimulation on pacemaker activity of the isolated sinus node of the young cat,” Circ Res. Nov. 1979;45(5):595-607.
Janes RD, Brandys JC, Hopkins DA, Johnstone DE, Murphy DA, and Armour JA., “Anatomy of human extrinsic cardiac nerves and ganglia,” American Journal of Cardiology; 1986; 57:299-308.
Kralios FA, Millar CK., “Sympathetic neural effects on regional atrial recovery properties and cardiac rhythm,” Am J Physiol. Apr. 1981;240(4):H590-96.
Lazarra R, Scherlag BJ, Robinson MJ, and Samet P., “Selective in situ parasympathetic control of the canine sinoatrial and atrioventricular nodes,” Circulation Research, 1973; 32:393-401.
Levy MN, Blattberg B., “Effect of vagal stimulation on the overflow of norepinephrine into the coronary sinus during cardiac sympathetic nerve stimulation in the dog,” Circ Res. Feb. 1976;38(2):81-5.
Lurie KG, Benditt D., “Syncope and the autonomic nervous system,” J Cardiovasc Electrophysiol. Aug. 1996;7(8):760-76.
Miyashita Y, Furukawa Y, Nakajima K, Hirose M, Kurogouchi F, Chiba S., “Parasympathetic inhibition of sympathetic effects on pacemaker location and rate in hearts of anesthetized dogs,” J Cardiovasc Electrophysiol. Aug. 1999;10(8):1066-76.
Murphy DA, Johnstone DE, and Armour JA., “Preliminary observations on the effects of stimulation of cardiac nerves in man,” Canadian Journal of Physiology and Pharmacology, 1985; 63:649-55.
Olgin JE, Sih HJ, Hanish S, Jayachandran JV, Wu J, Zheng QH, Winkle W, Mulholland GK, Zipes DP, Hutchins G., “Heterogeneous atrial denervation creates substrate for sustained atrial fibrillation,” Circulation. Dec.
Getzow Scott M
Heimbecher & Assoc. , LLC
St. Jude Medical, Atrial Fibrillation Division, Inc.
LandOfFree
Use of autonomic nervous system neurotransmitters inhibition... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Use of autonomic nervous system neurotransmitters inhibition..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of autonomic nervous system neurotransmitters inhibition... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4262987